anti sirpb1 antibodies  (Proteintech)

Journal: PLOS One

Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

doi: 10.1371/journal.pone.0359269

Figure Lengend Snippet: Antibodies used for in vitro investigations.

Article Snippet: OX-41 , Rabbit , Monoclonal , Novus , NBP1–03074 , – , 4.

Techniques: In Vitro

Journal: PLOS One

Article Title: AZP2006 in Parkinson’s disease models: A promising new neuroprotective treatment involving lysosomal homeostasis and the Progranulin/Prosaposin complex

doi: 10.1371/journal.pone.0359269

Figure Lengend Snippet: ICC analysis of cultures shows the total number of TH(+) neurons (A) and the length of their neurite network neurons (B) and microglia activation as area of OX-41(+) staining (C), expressed as % of control. Raw values for control (CTR) (i.e., 100%); sum TH(+) neurons per well, i.e., per biological replicate = 81 ± 4.0; neurite network = 2332 ± 112 µm; OX-41(+) area/field = 1421 ± 67 µm 2 . Each bar represents the mean ± SEM, one-way ANOVA followed by Fisher’s test. ### p < 0.001 or #### p < 0.0001 from CTR; **p < 0.01, ***p < 0.001 and ****p < 0.0001 from α-syn injury, (n = 4-6 / group).

Article Snippet: OX-41 , Rabbit , Monoclonal , Novus , NBP1–03074 , – , 4.

Techniques: Analysis, Activation Assay, Staining, Control

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: SIRPB1 is highly expressed in cutaneous malignant melanoma (MM) (A) The boxplot illustrates the SIRPB1 expression level in 461 cutaneous MM tumor tissues (T) vs. 558 nontumor tissues (N) obtained from the genotype-tissue expression (GTEx) and The Cancer Genome Atlas (TCGA) databases. (B) SIRPB1 expression in primary and metastatic tumor samples was compared using TCGA datasets. (C) Representative immunohistochemistry staining images of SIRPB1 expression in cutaneous MM and adjacent normal tissues from eight patients. 200× and 400× magnifications. Scale bars: 50 μm (above), 25 μm (below). (D) Validation of SIRPB1 mRNA expression in melanoma cell lines (A2058, A375, HMCB, and SK-MEL-1) and human epidermal melanocytes (HEMs) by qRT-PCR. (E) Validation of SIRPB1 protein expression in melanoma cell lines and HEM by Western blot (WB). β-Actin indicates control. All data are expressed as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Expressing, Immunohistochemistry, Staining, Biomarker Discovery, Quantitative RT-PCR, Western Blot, Control

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: SIRPB1 expression is transcriptionally regulated by USF2 (A) Seven transcription factors (TFs) bound to an SIRPB1 promoter were obtained from the JASPAR database. (B) Expression levels of seven TFs in normal tissues and malignant melanoma (MM) tissues were obtained from the TCGA database. (C) Relationship between SIRPB1 expression and the seven TFs was determined by conducting Spearman’s correlation analyses in MM samples from the TCGA database. (D) Transfection efficiency of the USF2 overexpression plasmid in A375 and A2058 cell lines was verified via a qRT-PCR analysis. (E) Transfection efficiency of the USF2 overexpression plasmid in A375 and A2058 cell lines was verified through a Western blot (WB) assay. (F) Effect of USF2 overexpression on SIRPB1 expression in A375 and A2058 cell lines was assessed by a qRT-PCR analysis. (G) Effect of USF2 overexpression on SIRPB1 expression in A375 and A2058 cell lines was evaluated through a WB assay. (H) Binding motif of USF2 on the SIRPB1 promoter. (I) Mutant sites of SIRPB1 in luciferase. (J) Fluorescence intensity in SIRPB1 wild type (WT) and mutant type (MUT) melanoma cells after transfection with the USF2 overexpression plasmid. All data are expressed as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Expressing, Transfection, Over Expression, Plasmid Preparation, Quantitative RT-PCR, Western Blot, Binding Assay, Mutagenesis, Luciferase, Fluorescence

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: SIRPB1 regulates the SOCS1/STAT3 signaling pathway in melanoma cells (A) GSEA plot show that SIRPB1 expression was significantly correlated with STAT3 in the TCGA MM dataset. (B and C) Protein expression levels of p -JAK2, p-STAT3, and SOCS1 in A375 and A2058 cells with SIRPB1 knockdown were determined using a Western blot (WB) assay. (D) Protein expression levels of p -JAK2, p-STAT3, and SOCS1 in mouse tissues with SIRPB1 knockdown were determined by a WB assay. (E) CCK-8 assay was performed to investigate the proliferation abilities of A375 cells treated with SIRPB1 knockdown and IL-6 (STAT3 agonist). (F) Clone-formation ability of A375 cells with and without SIRPB1 knockdown and IL-6 treatment was evaluated by conducting a colony-formation assay. (G) Migration activity and proliferation abilities of A375 cells with and without SIRPB1 knockdown and IL-6 treatment were analyzed by a Transwell assay. Scale bars, 50 μm. (H) Invasion activity of A375 cells with and without SIRPB1 knockdown and IL-6 treatment was assessed by a Transwell assay. Scale bars, 50 μm. All data are expressed as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Expressing, Knockdown, Western Blot, CCK-8 Assay, Colony Assay, Migration, Activity Assay, Transwell Assay

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: SIRPB1 knockdown suppresses the proliferation, migration, and invasion of two melanoma cell lines in vitro (A) The SIRPB1 expression levels in A375 and A2058 cell lines treated with three different lentiviral SIRPB1 short hairpin RNAs (shRNA) were assessed by qRT-PCR. (B) The knockdown efficiency of SIRPB1 in A375 and A2058 cell lines treated with three different lentiviral SIRPB1 shRNAs was determined using Western blot (WB). (C) Effects of SIRPB1 inhibition on the proliferation ability of A375 and A2058 cell lines were assessed by the cell counting Kit-8 (CCK8) assay in the negative control (NC), shSIRPB1-1, and shSIRPB1-2 groups. (D) Effects of SIRPB1 knockdown on the clone-formation ability of A375 and A2058 cells were evaluated by colony formation assay in three groups. (E) Effects of SIRPB1 knockdown on A375 and A2058 cell migration were analyzed by a Transwell assay. Scale bars, 50 μm. (F) Effects of SIRPB1 knockdown on A375 and A2058 cell invasion were assessed by Transwell assay in three groups. Scale bars, 50 μm. All data are expressed as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Knockdown, Migration, In Vitro, Expressing, shRNA, Quantitative RT-PCR, Western Blot, Inhibition, Cell Counting, CCK-8 Assay, Negative Control, Colony Assay, Transwell Assay

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: SIRPB1 knockdown attenuates the growth of melanoma cells in vivo (A) Comparison of tumor weight and volumes in a mouse model implanted with A375-shNC or A375-shSIRPB1 cells ( n = 6/group). The tumor weight of each group was measured at the end of the experiments. The right panel shows the tumor growth curve. Tumor volumes were measured every three days after tumor cell inoculation. (B–F) Effects of SIRPB1 knockdown on the expressions of SIRPB1, MMP2, PCNA, Ki67, and Snail in xenografted tumor tissues were assessed by immunofluorescence assay. Scale bars, 25 μm. (G) Immunofluorescence assays show that SIRPB1 knockdown suppressed these factors in xenografted tumor tissues. All data are expressed as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Knockdown, In Vivo, Comparison, Immunofluorescence

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: USF2 exerts an oncogenic effect in MM, which is reversed by SIRPB1 knockdown (A and B) Effect of USF2 overexpression with and without SIRPB1 knockdown on A2058 cells was assessed using qRT-PCR/WB. (C) Effect of USF2 overexpression with and without SIRPB1 knockdown on the A2058 cell-proliferation ability was investigated by a CCK8 assay. (D) Effect of USF2 overexpression with and without SIRPB1 knockdown on the clone-formation ability of A2058 cells was evaluated by conducting a colony-formation assay. (E) Effect of USF2 overexpression with and without SIRPB1 knockdown on the migration abilities of A2058 cells was analyzed by a Transwell assay. Scale bars, 50 μm. (F) Effect of USF2 overexpression with and without SIRPB1 knockdown on the invasion abilities of A2058 cells was assessed by a Transwell assay. Scale bars, 50 μm. All data are expressed as mean ± SD. ∗ p < 0.05, ∗∗ p < 0.01, and ∗∗∗ p < 0.001.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Knockdown, Over Expression, Quantitative RT-PCR, CCK-8 Assay, Colony Assay, Migration, Transwell Assay

Journal: iScience

Article Title: SIRPB1 is transcriptionally regulated by USF2 and promotes cutaneous malignant melanoma tumorigenicity through SOCS1/STAT3 signaling

doi: 10.1016/j.isci.2025.114080

Figure Lengend Snippet: Molecular mechanism of SIRPB1 on cutaneous MM tumorigenicity through SOCS1/STAT3 signaling USF2 promotes SIRPB1 transcription. The upregulation of SIRPB1 expression inhibits the expression of SOCS1. Down-regulation of SOCS1 expression increases the phosphorylation of STAT3. These effects promote the proliferation, migration, and invasion of melanoma cells.

Article Snippet: The slides were then incubated overnight with primary anti-SIRPB1 antibodies (11811-1-AP, Proteintech) at 1:100.

Techniques: Expressing, Phospho-proteomics, Migration